Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.69 |
| ▸ | NPY1R | P25929 | 10/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY2R | P49146 | 6/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577665 | 1.00 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29483775 | 0.97 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30866929 | 0.97 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29969342 | 0.97 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3217302 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29637447 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL3217285 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30400394 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30309215 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29637467 | 0.95 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161505-A1 | CD206 Targeted Peptide Conjugates and Methods of Using the Same | THE UAB RESEARCH FOUNDATION | 2025-05-22 | — | — | US | disclosed |
| WO-2023154564-A9 | CD206 TARGETED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME | Riptide Bioscience, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023154564-A2 | CD206 TARGETED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME | Riptide Bioscience, Inc. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161505-A1 | CD206 Targeted Peptide Conjugates and Methods of Using the Same | CD209, SIGLEC7, SIGLEC9 | NPY4R 727/4885NPY1R 1039/4885NPY5R 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.